Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has 5 years of Current Deferred Revenue data on record, last reported at $600000.0 in Q3 2023.

  • On a quarterly basis, Current Deferred Revenue rose 50.0% to $600000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $600000.0, a 50.0% increase, with the full-year FY2022 number at $900000.0, down 71.88% from a year prior.
  • Current Deferred Revenue reached $600000.0 in Q3 2023 per FULC's latest filing, up from $513000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for FULC hit a ceiling of $14.9 million in Q4 2020 and a floor of $400000.0 in Q3 2022.
  • A 5-year average of $4.1 million and a median of $2.0 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 273.78% in 2020, then tumbled 89.28% in 2022.
  • Tracing FULC's Current Deferred Revenue over 5 years: stood at $4.0 million in 2019, then skyrocketed by 273.78% to $14.9 million in 2020, then plummeted by 78.54% to $3.2 million in 2021, then tumbled by 71.88% to $900000.0 in 2022, then tumbled by 33.33% to $600000.0 in 2023.
  • Business Quant data shows Current Deferred Revenue for FULC at $600000.0 in Q3 2023, $513000.0 in Q2 2023, and $737000.0 in Q1 2023.